ZNTL – Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc.ZNTL
$1.21Name : Zentalis Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $87,061,808.00
EPSttm : -2.33
Zentalis Pharmaceuticals, Inc.
$1.21
6.20%$0.08Float Short %
10.71
Margin Of Safety %
Put/Call OI Ratio
1.57
EPS Next Q Diff
0.04
EPS Last/This Y
0.08
EPS This/Next Y
Price
1.21
Target Price
6.4
Analyst Recom
2.11
Performance Q
-41.83
Relative Volume
0.89
Beta
1.65
Ticker: ZNTL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | ZNTL | 1.22 | 0.81 | 0.00 | 1511 |
| 2025-04-15 | ZNTL | 1.275 | 0.81 | 0.00 | 1511 |
| 2025-04-16 | ZNTL | 1.265 | 0.81 | 0.00 | 1511 |
| 2025-04-17 | ZNTL | 1.3 | 0.81 | 0.00 | 1511 |
| 2025-04-18 | ZNTL | 1.29 | 0.81 | 1.67 | 1512 |
| 2025-04-21 | ZNTL | 1.36 | 2.03 | 0.00 | 897 |
| 2025-04-22 | ZNTL | 1.465 | 2.02 | 10.00 | 898 |
| 2025-04-23 | ZNTL | 1.495 | 2.02 | 10.00 | 898 |
| 2025-04-24 | ZNTL | 1.515 | 2.02 | 10.00 | 898 |
| 2025-04-25 | ZNTL | 1.43 | 2.0538720538721 | 0 | 907 |
| 2025-04-28 | ZNTL | 1.42 | 2.0538720538721 | 0 | 907 |
| 2025-04-29 | ZNTL | 1.37 | 2.05 | 0.00 | 907 |
| 2025-04-30 | ZNTL | 1.41 | 2.05 | 0.00 | 907 |
| 2025-05-01 | ZNTL | 1.455 | 1.58 | 0.00 | 997 |
| 2025-05-02 | ZNTL | 1.445 | 1.57 | 0.00 | 998 |
| 2025-05-05 | ZNTL | 1.365 | 1.57 | 0.00 | 998 |
| 2025-05-06 | ZNTL | 1.24 | 1.57 | 0.00 | 998 |
| 2025-05-07 | ZNTL | 1.23 | 1.57 | 0.00 | 998 |
| 2025-05-08 | ZNTL | 1.26 | 1.57 | 10.00 | 999 |
| 2025-05-09 | ZNTL | 1.225 | 1.57 | 10.00 | 999 |
| 2025-05-12 | ZNTL | 1.285 | 1.57 | 10.00 | 999 |
| 2025-05-13 | ZNTL | 1.21 | 1.57 | 10.00 | 999 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | ZNTL | 1.22 | -533.5 | - | -2.25 |
| 2025-04-15 | ZNTL | 1.27 | -533.5 | - | -2.25 |
| 2025-04-16 | ZNTL | 1.27 | -533.5 | - | -2.25 |
| 2025-04-17 | ZNTL | 1.29 | -533.5 | - | -2.25 |
| 2025-04-18 | ZNTL | 1.29 | -533.5 | - | -2.25 |
| 2025-04-21 | ZNTL | 1.36 | -533.5 | - | -2.25 |
| 2025-04-22 | ZNTL | 1.47 | -533.5 | - | -2.25 |
| 2025-04-23 | ZNTL | 1.50 | -533.5 | - | -2.25 |
| 2025-04-24 | ZNTL | 1.51 | -533.5 | - | -2.25 |
| 2025-04-25 | ZNTL | 1.43 | -533.5 | - | -2.25 |
| 2025-04-28 | ZNTL | 1.42 | -533.5 | - | -2.25 |
| 2025-04-29 | ZNTL | 1.37 | -533.5 | - | -2.25 |
| 2025-04-30 | ZNTL | 1.42 | -533.5 | - | -2.25 |
| 2025-05-01 | ZNTL | 1.45 | -533.5 | - | -2.25 |
| 2025-05-02 | ZNTL | 1.45 | -533.5 | - | -2.25 |
| 2025-05-05 | ZNTL | 1.36 | -533.5 | - | -2.25 |
| 2025-05-06 | ZNTL | 1.24 | -533.5 | - | -2.25 |
| 2025-05-07 | ZNTL | 1.23 | -533.5 | - | -2.25 |
| 2025-05-08 | ZNTL | 1.26 | -533.5 | - | -2.25 |
| 2025-05-09 | ZNTL | 1.23 | -533.5 | - | -2.25 |
| 2025-05-12 | ZNTL | 1.29 | -533.5 | - | -2.25 |
| 2025-05-13 | ZNTL | 1.21 | -533.5 | - | -2.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-15 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-16 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-17 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-18 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-21 | ZNTL | 0.50 | -6.91 | 8.83 |
| 2025-04-22 | ZNTL | 0.50 | -6.91 | 8.83 |
| 2025-04-23 | ZNTL | 0.50 | -6.91 | 8.83 |
| 2025-04-24 | ZNTL | 0.50 | -6.91 | 8.83 |
| 2025-04-25 | ZNTL | 0.50 | -6.91 | 8.83 |
| 2025-04-28 | ZNTL | 0.50 | -7.20 | 9.75 |
| 2025-04-29 | ZNTL | 0.50 | -7.20 | 9.75 |
| 2025-04-30 | ZNTL | 0.50 | -7.20 | 9.75 |
| 2025-05-01 | ZNTL | 0.62 | -7.20 | 9.75 |
| 2025-05-02 | ZNTL | 0.62 | -7.20 | 9.75 |
| 2025-05-05 | ZNTL | 0.62 | -7.47 | 9.73 |
| 2025-05-06 | ZNTL | 0.62 | -7.47 | 9.73 |
| 2025-05-07 | ZNTL | 0.62 | -7.47 | 9.73 |
| 2025-05-08 | ZNTL | 0.62 | -7.47 | 9.74 |
| 2025-05-09 | ZNTL | 0.62 | -7.47 | 9.74 |
| 2025-05-12 | ZNTL | 0.62 | -5.41 | 10.71 |
| 2025-05-13 | ZNTL | 0.63 | -5.41 | 10.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.66
Avg. EPS Est. Current Quarter
-0.62
Avg. EPS Est. Next Quarter
-0.62
Insider Transactions
0.63
Institutional Transactions
-5.41
Beta
1.65
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
21
Growth Score
25
Sentiment Score
59
Actual DrawDown %
98.6
Max Drawdown 5-Year %
-98.8
Target Price
6.4
P/E
Forward P/E
PEG
P/S
1.29
P/B
0.26
P/Free Cash Flow
EPS
-2.33
Average EPS Est. Cur. Y
-2.25
EPS Next Y. (Est.)
-2.25
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-245.96
Relative Volume
0.89
Return on Equity vs Sector %
-72.9
Return on Equity vs Industry %
-55.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.21
EBIT Estimation
Zentalis Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 166
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.
stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today
news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance
stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market
stock prices ZNTL premarket after hours
ticker ZNTL fair value insiders trading